Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,521 signal articles · 27 in last 24h · 122,266 total before filter · latest 1h ago
27last 24h
1255last 7d
211● bullish (7d)
150● bearish (7d)
205publishers
AllMacro211Earnings431M&A96Regulatory23Product9Analyst11
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
OpenAI Is Adding Two Independent Board Members Ahead of IPO
The Wall Street Journal32d agoneutral
OpenAI Is Adding Two Independent Board Members Ahead of IPO

OpenAI is adding David Vélez, founder and global chief executive of Nubank, a Latin American digital services firm, and Robin Vince, the chief executive of Bank of New York Mellon to its board of directors, the company said. Vince will chair the audit committee, OpenAI said. The company has worked to improve its corporate governance after a previous set of directors abruptly fired Chief Executive Sam Altman three years ago for what they described as a lack of candor in his communications, throwing the company into disarray.

Treasury Yields Higher Ahead of Fed Meeting
Barrons.com32d agoneutral
Treasury Yields Higher Ahead of Fed Meeting

Treasury's fell sending yields higher, concluding a day of light U.S. economic data ahead of the Federal Reserve's interest rate meeting next week. Brent crude futures added 2% to settle above $90 a barrel.

Bloomberg32d agoneutral
OpenAI Names BNY, Nubank CEOs to Board Ahead of IPO

(Bloomberg) -- OpenAI has appointed two financial services executives to its board of directors, drawing on their experience as the company moves toward a Wall Street debut. Most Read from BloombergApple to Launch ‘Upgrade’ Device Leasing Program With Klarna to Spur SalesChina AI Sensation Moonshot’s Gamble on Big Models Pays OffYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Th

Broadcom stands to gain from new cloud deal
TheStreet32d agoneutral
Broadcom stands to gain from new cloud deal

Broadcom (AVGO) just landed a customer that most investors will never think about when they buy the stock. Broadcom is currently known for one thing: custom AI chips. Yet the deal that could matter most for the next few years has nothing to do with silicon. On July 16, 2026, Broadcom and Standard ...

Twilio faces higher bar heading into quarterly earnings, says Jefferies
Proactive32d agoneutral
Twilio faces higher bar heading into quarterly earnings, says Jefferies

Twilio Inc (NYSE:TWLO) is expected to deliver second quarter results that exceed expectations on revenue and operating income, with investors likely to focus on whether the communications software company's gross profit growth can remain in the mid-teens during the second half of the year,...

📈 Earnings Snippet: Northrop Grumman
The Wall Street Journal32d agoneutral
📈 Earnings Snippet: Northrop Grumman

The defense and aerospace company said Tuesday that it expects $43.75 billion to $44.25 billion in sales in 2026, adding a quarter-billion dollars to its previous targets. Adjusted earnings are now projected at $28.

The World Cup effect leaves airlines with a tougher test
TheStreet32d agoneutral
The World Cup effect leaves airlines with a tougher test

The World Cup produced the sort of demand shock airlines crave, with international travelers booking late, accepting connections and paying unusually high fares. But that didn’t change the economics of the industry. American Airlines (AAL) added 27,000 seats on 12 routes and offered 1.45 million ...

Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Reuters Videos32d agoneutralVIDEO
Novo sues Lilly, claiming misleading ads in weight-loss drug battle

<body><p>STORY: :: Novo Nordisk claims misleading ads in Eli Lilly weight-loss drug lawsuit</p><p>:: July 21, 2026</p><p>:: Maggie Fick, European Pharma Industry Correspondent</p><p>"Novo Nordisk sued rival Eli Lilly in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising and claiming its weight-loss medicines outperform Novo's drugs." //</p><p>"Novo is alleging in its suit that Lilly's advertisements compare weight-loss results of about 50 pounds for its drug Zepbound with about 33 pounds for Wegovy, even though no head-to-head clinical trial has compared the highest approved doses of the medicines."</p><p>"Pharmaceutical companies regularly sue each other over claims related to patent infringement, for example, but false advertising suits, such as the one filed today, are less common."</p><p>"Novo Nordisk was first to market with its weight-loss injection Wegovy several years ago, but it later lost the lead to Eli Lilly, after that company launched a rival injection called Zepbound in the United States. Last year, Novo replaced its CEO and was forced to issue multiple profit warnings as it fell further behind Eli Lilly in this really competitive and booming obesity drug market, which analysts expect to be worth more than $100 billion by 2030. This year, Novo has actually sort of landed a counterpunch with its oral Wegovy pill. It was able to launch that drug ahead of Eli Lilly. Lilly has, in April, launched its own pill, a weight-loss pill. But Novo has managed to keep up strong sales even since the launch of Lilly's pill."</p><p>"Both companies report quarterly results in the next couple of weeks."</p><p>:: Novo Nordisk</p><p>:: Eli Lilly</p><p>The Danish company filed the lawsuit in U.S. District Court ‌in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.</p><p>Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo's Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.</p><p>But Indianapolis-based Eli Lilly said it stands firmly behind its ads, which are based on the results of its SURMOUNT-5 trial. That ⁠trial — completed in 2024 — compared patients on 10 mg or 15 mg of Lilly's Zepbound to patients on 1.7 mg or 2.4 mg doses of Wegovy. The FDA approved ​a 7.2 mg dose of Wegovy in March of this year.</p></body>